Cargando…

Causal relationships between risk of venous thromboembolism and 18 cancers: a bidirectional Mendelian randomisation analysis

BACKGROUND: People with cancer experience high rates of venous thromboembolism (VTE). Additionally, risk of subsequent cancer is increased in people experiencing their first VTE. The causal mechanisms underlying this association are not completely understood, and it is unknown whether VTE is itself...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornish, Naomi, Haycock, Philip, Brenner, Hermann, Figueiredo, Jane C., Galesloot, Tessel, Grant, Robert C, Johansson, Mattias, Mariosa, Daniela, McKay, James, Pai, Rish, Pellatt, Andrew J, Samadder, N. Jewel, Shi, Jianxin, Thibord, Florian, Trégouët, David-Alexandre, Voegele, Catherine, Thirlwell, Chrissie, Mumford, Andrew, Langdon, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246038/
https://www.ncbi.nlm.nih.gov/pubmed/37292802
http://dx.doi.org/10.1101/2023.05.16.23289792
Descripción
Sumario:BACKGROUND: People with cancer experience high rates of venous thromboembolism (VTE). Additionally, risk of subsequent cancer is increased in people experiencing their first VTE. The causal mechanisms underlying this association are not completely understood, and it is unknown whether VTE is itself a risk factor for cancer. METHODS: We used data from large genome-wide association study meta-analyses to perform bi-directional Mendelian randomisation analyses to estimate causal associations between genetically-proxied lifetime risk of VTE and risk of 18 different cancers. RESULTS: We found no conclusive evidence that genetically-proxied lifetime risk of VTE was causally associated with an increased incidence of cancer, or vice-versa. We observed an association between VTE and pancreatic cancer risk (odds ratio for pancreatic cancer 1.23 (95% confidence interval 1.08 - 1.40) per log-odds increase in risk of VTE, P = 0.002). However, sensitivity analyses revealed this association was predominantly driven by a variant proxying non-O blood group, with inadequate evidence from Mendelian randomisation to suggest a causal relationship. CONCLUSIONS: These findings do not support the hypothesis that genetically-proxied lifetime risk of VTE is a cause of cancer. Existing observational epidemiological associations between VTE and cancer are therefore more likely to be driven by pathophysiological changes which occur in the setting of active cancer and anti-cancer treatments. Further work is required to explore and synthesise evidence for these mechanisms.